Financings in Brief: Anika Research
This article was originally published in The Gray Sheet
Anika Research: Hyaluronic acid product manufacturer closes a $2.4 mil. private equity financing sale of 120,000 units, each consisting of a share of convertible preferred stock with a 9% annual dividend rate and a warrant to purchase preferred stock. Axiom Venture Partners purchased $2 mil. of the units, as announced previously ("The Gray Sheet" May 8, p. 14). In addition, "certain officers and directors of Anika purchased $400,000 of units," the company says...
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.